214 related articles for article (PubMed ID: 18518768)
21. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
[TBL] [Abstract][Full Text] [Related]
22. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
23. Effect of Regulatory T Cells on Promoting Apoptosis of T Lymphocyte and Its Regulatory Mechanism in Sepsis.
Luan YY; Yin CF; Qin QH; Dong N; Zhu XM; Sheng ZY; Zhang QH; Yao YM
J Interferon Cytokine Res; 2015 Dec; 35(12):969-80. PubMed ID: 26309018
[TBL] [Abstract][Full Text] [Related]
24. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity.
Bianchini R; Bistoni O; Alunno A; Petrillo MG; Ronchetti S; Sportoletti P; Bocci EB; Nocentini G; Gerli R; Riccardi C
Eur J Immunol; 2011 Aug; 41(8):2269-78. PubMed ID: 21557210
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for human glioma: innovative approaches and recent results.
Hussain SF; Heimberger AB
Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048
[TBL] [Abstract][Full Text] [Related]
26. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.
Li L; Chao QG; Ping LZ; Xue C; Xia ZY; Qian D; Shi-ang H
Cancer Biother Radiopharm; 2009 Jun; 24(3):357-67. PubMed ID: 19538059
[TBL] [Abstract][Full Text] [Related]
27. Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+ CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival.
Hiraki S; Ono S; Tsujimoto H; Kinoshita M; Takahata R; Miyazaki H; Saitoh D; Hase K
Surgery; 2012 Feb; 151(2):313-22. PubMed ID: 21982068
[TBL] [Abstract][Full Text] [Related]
28. Endothelin B receptor promotes the proliferation and immune escape of malignant gliomas.
Pan DS; Feng SZ; Cao P; Li JJ
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1230-1235. PubMed ID: 28841806
[TBL] [Abstract][Full Text] [Related]
29. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.
Hussain SF; Yang D; Suki D; Aldape K; Grimm E; Heimberger AB
Neuro Oncol; 2006 Jul; 8(3):261-79. PubMed ID: 16775224
[TBL] [Abstract][Full Text] [Related]
30. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.
Grauer OM; Nierkens S; Bennink E; Toonen LW; Boon L; Wesseling P; Sutmuller RP; Adema GJ
Int J Cancer; 2007 Jul; 121(1):95-105. PubMed ID: 17315190
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for malignant gliomas.
Bloch O
Cancer Treat Res; 2015; 163():143-58. PubMed ID: 25468230
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
34. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
35. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
Chen W; Jin W; Hardegen N; Lei KJ; Li L; Marinos N; McGrady G; Wahl SM
J Exp Med; 2003 Dec; 198(12):1875-86. PubMed ID: 14676299
[TBL] [Abstract][Full Text] [Related]
36. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors.
Morford LA; Dix AR; Brooks WH; Roszman TL
J Neurosurg; 1999 Dec; 91(6):935-46. PubMed ID: 10584838
[TBL] [Abstract][Full Text] [Related]
37. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
Weller M; Fontana A
Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
[TBL] [Abstract][Full Text] [Related]
38. Immune defects observed in patients with primary malignant brain tumors.
Dix AR; Brooks WH; Roszman TL; Morford LA
J Neuroimmunol; 1999 Dec; 100(1-2):216-32. PubMed ID: 10695732
[TBL] [Abstract][Full Text] [Related]
39. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Heimberger AB; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Sun W; Qiao W; Hiraoka N; Fuller GN
Clin Cancer Res; 2008 Aug; 14(16):5166-72. PubMed ID: 18698034
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells.
Cools N; Van Tendeloo VF; Smits EL; Lenjou M; Nijs G; Van Bockstaele DR; Berneman ZN; Ponsaerts P
J Cell Mol Med; 2008 Apr; 12(2):690-700. PubMed ID: 18419605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
